Total votes: 4

Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases.

The company's first product, Aridol, is now registered for sale in Australia, Europe and South East Asia and a request for marketing approval has been filed in the United States. Aridol is designed to assist in the management of both asthma and chronic obstructive pulmonary disease.

The Company's second product, Bronchitol, has completed the first regulatory Phase 3 trials in both cystic fibrosis and bronchiectasis. Bronchitol is designed to restore normal lung hydration, improve lung function and to help relieve the mucus burden in the lungs of patients suffering from chronic respiratory conditions.

The company's other application area is chronic obstructive pulmonary disease (COPD) and is the largest market opportunity. COPD is a lung disease that makes it hard to breathe. It is caused by damage to the lungs over many years, usually from smoking. COPD includes Chronic bronchitis and Emphysema

Cash & Cash Equivalents at end of 1st Jul 2010: $86M.

Some Previous & Current Institutional Investors: ANZ Nominees Limited, JP Morgan Nominees Australia Limited, Citicorp Nominees Pty Limite, CM Capital

Possible Competition & Similar Companies:
Vertex Pharmaceuticals for Cystic Fibrosis (San Diego)
   - click here to see on our USA sister website, USA site requires separate log-in

Upcoming Events:

Jul-Sep 2010, Pharmaxis will now move forward to meet the U.S. Food & Drug Administration (FDA) to discuss a New Drug Application (NDA) for Bronchitol.

Sep-Dec 2010 Submission to the European regulatory authority (EMA) of further the safety data from CF302 to receive a decision later this year for Bronchitol - Cystic Fibrosis.

Also possible in the coming months:

PXS25 starts Phase 1A clinical trial